Article metrics
PDF
Other content recommended for you
- Update on disease-modifying therapies for multiple sclerosis
- ▼Fingolimod for multiple sclerosis
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis
- Tumefactive demyelination: an approach to diagnosis and management
- Disease modifying therapies for relapsing multiple sclerosis
- Fingolimod in multiple sclerosis: profile of use in habitual practice
- Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?
- SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod